At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 309 enrolled
Drug / intervention
Daytranadrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IV, Multi-center, Open-label Study of DAYTRANA (Methylphenidate Transdermal System [MTS]) to Characterize the Dermal Reactions in Pediatric Patients Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD).
In Brief
A Phase 4 clinical trial evaluating Daytrana for Attention Deficit Hyperactivity Disorder. Completed, enrolled 309 participants across 29 sites.
Detailed Summary
This is a study designed to characterize the dermal response of DAYTRANA. Subjects will visit the study site over a period of approximately 14 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttention Deficit Hyperactivity Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2007
First PostedFeb 2007
Primary CompletionAug 2007
Study CompletionJul 2008
TodayJul 2026
First PostedFeb 13, 2007
Enrollment StartJan 1, 2007
Primary CompletionAug 1, 2007
Study CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 19.4 years ago
Interventions
Daytranadrug
Methylphenidate Transdermal System (MTS)